MCID: PRS045
MIFTS: 38

Prostatic Hypertrophy malady

Summaries for Prostatic Hypertrophy

Sources:
64Wikipedia, 33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
Wikipedia:64 Benign prostatic hyperplasia (BPH), also called benign enlargement of the prostate (BEP),... more...

MalaCards: Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to adenocarcinoma and prostatic adenoma. An important gene associated with Prostatic Hypertrophy is SRY (sex determining region Y), and among its related pathways is Cell death signalling via NRAGE, NRIF and NADE. The compounds tamsulosin and chlormadinone acetate have been mentioned in the context of this disorder.

Aliases & Classifications for Prostatic Hypertrophy

Sources:
8Disease Ontology, 10DISEASES, 61UMLS
See all sources

Aliases & Descriptions:

prostatic hypertrophy 8 10
benign prostatic hypertrophy 61


External Ids:

Disease Ontology8 DOID:11132

Related Diseases for Prostatic Hypertrophy

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 91)
idRelated DiseaseScoreTop Affiliating Genes
1adenocarcinoma30.5KLK3, ACPP, PROS1, PCNA, F2RL1, SRD5A1
2prostatic adenoma30.4ACPP, KLK3, SRD5A1
3adenoma30.4GSTP1, SRD5A1, ACPP, PCNA, SHBG, F2RL1
4urinary tract obstruction30.2SRD5A1, KLK3
5urethral stricture30.0KLK3
6klinefelter's syndrome30.0FGF8, CYP19A1, SHBG, SRD5A1
7prostatic cyst10.4
8neurogenic bladder10.2
9acute myocardial infarction10.2
10testicular cancer10.2
11urethral obstruction10.2
12nephrogenic adenoma10.0
13prolactinoma10.0
14bladder neck obstruction10.0
15osteoarthritis10.0
16acute pyelonephritis10.0
17kidney hypertrophy10.0
18prostate lymphoma10.0
19adrenal carcinoma10.0
20acute kidney failure10.0
21bladder disease10.0
22urethra cancer10.0
23uterine disease10.0
24syncope10.0
25venous thrombosis10.0
26coronary heart disease10.0
27epididymitis10.0
28nephritis10.0
29hermaphroditism10.0SRY
30gonadal dysgenesis10.0SRY
31gastroparesis10.0PHF20
32hypoactive sexual desire disorder10.0SHBG
33periodontal disease10.0ACPP
3446xx sex reversal 110.0SRD5A1, SRY
35lupus erythematosus10.0PROS1
36pituitary adenoma10.0PCNA
37mixed gonadal dysgenesis10.0SRY, SRD5A1
38hypopituitarism10.0SHBG
39ovarian hyperstimulation syndrome10.0CYP19A1
40alopecia10.0SHBG
41cervical cancer10.0SRD5A1, GSTP1
42male infertility10.0SHBG
43arthritis10.0ACPP, F2RL1
44pseudohermaphroditism10.0CYP19A1, SRY
45galactosemia10.0PCNA
46hypospadias10.0SRD5A1, SRY, FGF8
47pancreatitis10.0F2RL1, GSTP1
48androgen insensitivity syndrome10.0SRD5A1, SHBG, SRY
49congenital adrenal hyperplasia10.0SRD5A1, SRY, CYP19A1
50endometriosis10.0CYP19A1

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to prostatic hypertrophy

Clinical Features for Prostatic Hypertrophy

Drugs & Therapeutics for Prostatic Hypertrophy

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials
See all sources

Approved drugs:

Search CenterWatch for Prostatic Hypertrophy

Drug clinical trials:

Search ClinicalTrials for Prostatic Hypertrophy

Search NIH Clinical Center for Prostatic Hypertrophy

Search CenterWatch for Prostatic Hypertrophy

Genetic Tests for Prostatic Hypertrophy

Anatomical Context for Prostatic Hypertrophy

Animal Models for Prostatic Hypertrophy or affiliated genes

Sources:
28inGenious Targeting Laboratory
See all sources

Publications for Prostatic Hypertrophy

Sources:
51PubMed
See all sources

Articles related to Prostatic Hypertrophy:

(show top 50)    (show all 507)
idTitleAuthorsYear
1
Management of benign prostatic hypertrophy-related urinary retention: current trends and perspectives. (20027550)
2009
2
Doxazosin in the treatment of benign prostatic hypertrophy: an update. (18046916)
2006
3
Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. (12581003)
2003
4
Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy. (12534901)
2002
5
Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription-event monitoring data. (11412215)
2001
6
Men's lived experiences following transurethral prostatectomy for benign prostatic hypertrophy. (10632793)
2000
7
Ammonium-chloride-induced prostatic hypertrophy in vitro: urinary ammonia as a potential risk factor for benign prostatic hyperplasia. (10550527)
1999
8
MRSA and minimally invasive treatments for benign prostatic hypertrophy. (9652696)
1998
9
Chlormadinone acetate pellet implantation plus short-term oral administration in dogs with benign prostatic hypertrophy. (9675615)
1998
10
Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy. (9759700)
1998
11
Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. (8821687)
1996
12
Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation. (8588267)
1995
13
Estimation of urethral resistance by curve fitting in the pressure-flow plot. Theory and experience in normal men and men with benign prostatic hypertrophy. (7539681)
1995
14
Benign prostatic hypertrophy. Options for management. (7518555)
1994
15
A novel canine model of partial outlet obstruction secondary to prostatic hypertrophy. (7532514)
1994
16
Benign prostatic hypertrophy. (7520031)
1994
17
Medical management of benign prostatic hypertrophy. (7533690)
1994
18
Current standards for the evaluation and pharmacological care of benign prostatic hypertrophy. Proceedings of a symposium. Genoa, Italy, July 22, 1992. (7687551)
1993
19
Prostatic growth factors and benign hypertrophy of the prostate. Current knowledge and perspectives]. (1284554)
1992
20
Benign prostatic hypertrophy. (1725588)
1991
21
Prazosin: an evaluation of its clinical efficacy and safety in the treatment of benign prostatic hypertrophy. (1690475)
1990
22
Closed prostatic commissurotomy. An endoscopic technique for the treatment of benign prostatic hypertrophy. (2463033)
1988
23
Pathophysiology and differential diagnosis of benign prostatic hypertrophy. (2462303)
1988
24
Development of benign prostatic hypertrophy estimated from ultrasonic measurement with long-term follow up. (2437669)
1987
25
Determination of androgen receptors in human benign prostatic hypertrophy with two synthetic radiolabeled ligands. (2425471)
1986
26
Ischemic heart disease in patients with large gland prostatic hypertrophy. (2579499)
1985
27
Candicidin in treatment of benign prostatic hypertrophy. (6209428)
1984
28
Studies on the role of sex-hormone-binding globulin (SHBG) in benign prostatic hypertrophy in men. I. Clinical research. (6206017)
1984
29
Progestin-binding protein in human benign prostatic hypertrophy. (6171422)
1981
30
Prostatitis and prostatodynia: their relationship to benign prostatic hypertrophy. (6154991)
1980
31
Benign prostatic hypertrophy: When should you consider prostatectomy for your patient? (87358)
1979
32
Testosterone metabolism in benign prostatic hypertrophy: in vivo studies of gestonorone caproate and cyproterone acetate. (64267)
1976
33
Patterns of urinary flow in benign prostatic hypertrophy. (61186)
1976
34
Recurrent benign prostatic hypertrophy. (66698)
1976
35
A systematic study of testosterone metabolism in benign prostatic hypertrophy (BPH): in vitro results. (49968)
1975
36
Steroid receptors in the human prostate. 1. Estradiol - 17beta binding in benign prostatic hypertrophy. (53911)
1975
37
Androgen-binding proteins in human benign prostatic hypertrophy. (51854)
1975
38
Benign prostatic hypertrophy treated with a gestagen. A double-blind clinical trial with randomized allocation. (4118753)
1972
39
In vivo uptake and metabolism of 3H-testosterone and 3H-5 -dihydrotestosterone by human benign prostatic hypertrophy. (4117573)
1972
40
Cryosurgery of prostatic hypertrophy. Late results. (4107716)
1971
41
The effect of 17-alpha-hydroxy-19-norprogesterone caproate (SH582) on benign prostatic hypertrophy. (4105896)
1971
42
Treatment of benign prostatic hypertrophy with progestational agents: a preliminary report. (4172531)
1968
43
The surgical anatomy of the benign prostatic hypertrophy. (4178905)
1968
44
Effect of progestational agents on gonadal and adrenal cortical function in patients with benign prostatic hypertrophy and carcinoma of the prostate. (4164338)
1967
45
Clinical observations on prostatic hypertrophy of 268 cases in the recent 15 years. (4161038)
1966
46
KLINEFELTER'S SYNDROME AND BENIGN PROSTATIC HYPERTROPHY. (14057110)
1963
47
Benign prostatic hypertrophy. (13416559)
1957
48
Prostatic hypertrophy: choice of operation; a review of personal experience. (13383420)
1957
49
The rationale of treating benign prostatic hypertrophy with combinations of testosterone and estrogen. (13306513)
1956
50
Differential diagnosis, benign prostatic hypertrophy, and neurogenic bladders. (18876120)
1948

Genetic Variations for Prostatic Hypertrophy

Expression for genes affiliated with Prostatic Hypertrophy

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Prostatic Hypertrophy

Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for genes affiliated with Prostatic Hypertrophy

Sources:
54Reactome
See all sources

Pathways related to Prostatic Hypertrophy according to GeneCards/GeneDecks:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Hide members
10.2ADRA1A, ADRA1D

Compounds for genes affiliated with Prostatic Hypertrophy

Sources:
29IUPHAR, 45Novoseek, 11DrugBank, 24HMDB, 60Tocris Bioscience, 50PharmGKB, 2BitterDB
See all sources

Compounds related to Prostatic Hypertrophy according to GeneCards/GeneDecks:

(show top 50)    (show all 138)
idCompoundScoreTop Affiliating Genes
1tamsulosin29 45 1112.5KLK3, ADRA1D, ADRA1A
2chlormadinone acetate4510.4ACPP, SHBG, KLK3
3atrazine4510.4SHBG, KLK3, CYP19A1
4dutasteride45 1111.4CYP19A1, SRD5A1, KLK3
5formestane4510.4SRD5A1, SHBG, CYP19A1
6estramustine phosphate4510.4KLK3, PROS1, ACPP
7epinephrine45 11 2412.4SHBG, ADRA1D, ADRA1A
8ment4510.3SRD5A1, KLK3, CYP19A1, SHBG
9androstenediol4510.3KLK3, SHBG, CYP19A1, SRD5A1
10alfuzosin45 1111.3ADRA1D, KLK3, SRD5A1, ADRA1A
11megestrol acetate4510.3CYP19A1, KLK3, SHBG
12terazosin45 1111.3ADRA1D, ADRA1A, SRD5A1, KLK3
13doxazosin45 1111.3ADRA1D, KLK3, SRD5A1, ADRA1A
14bicalutamide45 60 1112.3KLK3, SRD5A1, ACPP, CYP19A1
155alpha-androstane-3alpha,17beta-diol4510.2SHBG, CYP19A1, SRD5A1
1617-hydroxyprogesterone45 2411.2CYP19A1, SRD5A1, SHBG, ACPP
17hydroxyflutamide45 2911.2KLK3, SRD5A1, SHBG
18lycopene45 2411.2SRD5A1, GSTP1, KLK3, PCNA
19diethylstilbestrol45 29 1112.2KLK3, SHBG, CYP19A1, ACPP
20ketoconazole45 29 11 2413.2KLK3, SHBG, CYP19A1, SRD5A1
21progestins4510.2KLK3, SHBG, CYP19A1, SRD5A1
22finasteride45 60 11 2413.2ACPP, KLK3, SHBG, SRD5A1, CYP19A1
23cyproteroneacetate4510.2CYP19A1, SRD5A1, KLK3, ACPP, SHBG
24deoxyribonucleic acid4510.2ACPP, SRY, PCNA, KLK3
25buserelin45 29 1112.1CYP19A1, KLK3, ACPP
26flutamide45 60 1112.1SHBG, KLK3, ACPP, SRD5A1, CYP19A1
27phentolamine29 45 1112.1ADRA1D, ADRA1A, PDE5A
28dehydroepiandrosterone sulfate4510.1SRD5A1, CYP19A1, SHBG, KLK3, ACPP
29dhea4510.1SRD5A1, ACPP, SHBG, KLK3, CYP19A1
30bromocriptine29 45 1112.1SHBG, ADRA1A, ADRA1D, PCNA
31leuprolide acetate4510.1KLK3, SHBG, CYP19A1
32biotin45 11 2412.1SRY, GSTP1, KLK3, SHBG, PCNA
33docetaxel45 50 60 1113.1KLK3, TUBD1, GSTP1, PROS1, CYP19A1
34estrogen4510.1KLK3, PDE5A, ACPP, SRD5A1
35estramustine45 1111.0PROS1, ACPP, KLK3
363-alpha-androstanediol glucuronide45 2411.0SHBG, KLK3, SRD5A1
37goserelin45 29 1112.0PROS1, ACPP, SHBG, KLK3, CYP19A1, SRD5A1
38dexamethasone45 50 29 1113.0PROS1, KLK3, SHBG, PCNA
39vitamin d459.9PROS1, SRD5A1, ACPP, CYP19A1, SHBG, KLK3
40dihydrotestosterone45 29 11 2412.9SRD5A1, ACPP, CYP19A1, SHBG, PROS1, KLK3
41gnrh459.9KLK3, SRD5A1, ACPP, CYP19A1, SHBG
42genistein45 29 60 2 11 2414.8F2RL1, CYP19A1, GSTP1, SHBG, SRD5A1, PCNA
43androstenedione45 2410.7SRD5A1, ACPP, SHBG, CYP19A1
44dopamine45 29 11 2412.7GSTP1, SRD5A1, F2RL1, FGF8, PCNA, SHBG
45steroid459.7CYP19A1, KLK3, PROS1, SHBG, ACPP, SRY
46exemestane50 45 60 1112.7CYP19A1, SHBG, SRD5A1
47estradiol45 11 2411.7KLK3, PCNA, SRY, ACPP, SHBG, SRD5A1
48vegf459.5GSTP1, F2RL1, PDE5A, ACPP, PCNA, KLK3
49arginine459.5F2RL1, ACPP, GSTP1, CYP19A1, PCNA, PROS1
50testosterone45 60 11 2412.2CYP19A1, SRD5A1, PCNA, SRY, ACPP, GSTP1

GO Terms for genes affiliated with Prostatic Hypertrophy

Sources:
16Gene Ontology
See all sources

Biological processes related to Prostatic Hypertrophy according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureGO:00199410.2ADRA1A, ADRA1D
2negative regulation of tumor necrosis factor-mediated signaling pathwayGO:01080410.1GSTP1, F2RL1
3leukocyte migrationGO:05090010.0F2RL1, SIRPA, PROS1
4positive regulation of superoxide anion generationGO:0329309.9GSTP1, F2RL1

Molecular functions related to Prostatic Hypertrophy according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1alpha1-adrenergic receptor activityGO:00493710.2ADRA1A, ADRA1D

Products for genes affiliated with Prostatic Hypertrophy

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Prostatic Hypertrophy

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet